Wednesday, 18 November 2026European Markets

ADOCIA Stock Bullish Momentum With A 14.57% Rise On Tuesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with adocia (adoc.pa) jumping 14.57% to €3.74 on tuesday while cac 40 fell 0.16% to €7,406.01.

adocia's last close was €3.26, 49.54% under its 52-week high of €6.46.

about adocia

adocia sa, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. its proprietary biochaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. the company's clinical product pipeline includes insulin formulations, such as biochaperone lispro u100 and u200, which are ultra-rapid formulations based on rapid insulin lispro; biochaperone combo, a combination of acting insulin glargine and rapid-acting insulin lispro; biochaperone lispram, a combination of prandial insulin with pramlintide; and biochaperone glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as m1pram, a metabolite of insulin glargine and pramlintide. its preclinical pipeline includes bi-hormonal products, which include biochaperone aspram, which is a combination of rapid insulin aspart with pramlintide; and biochaperone glargine liraglutidea, which is a fixed combination of insulin glargine with an analogue of the glp-1 receptor. in addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including biochaperone gluexe, which is a combination of glucagon and exenatide; pramexe, which is a combination of pramlintide and exenatide; and biochaperone pramgluexe, which is a triple combination of pramlintide, glucagon and exenatide. it has a strategic alliance with tonghua dongbao pharmaceutical co., ltd. to develop and commercialize biochaperone lispro and biochaperone combo in china and other asian and middle eastern territories. the company was incorporated in 2005 and is headquartered in lyon, france.

earnings per share

as for profitability, adocia has a trailing twelve months eps of €-0.78.

more news about adocia (adoc.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 16 May 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›